Sun Pharma share price: Sun Pharmaceutical’s shares declined following a reported 20% YoY drop in Q1FY26 net profit, despite a 10% increase in revenue. Brokerages offer mixed recommendations: Nuvama suggests ‘Hold,’ while Avendus upgrades to ‘Add,’ anticipating future gains from India formulations and innovative drugs. Motilal Oswal maintains a ‘Buy’ rating, citing a strong portfolio, but lowers the target price due to increased expenses.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets